India issues alert to deter use of Roche's Avastin drug for eyes

Image
Reuters NEW DELHI
Last Updated : Jan 21 2016 | 10:07 PM IST

By Aditya Kalra

NEW DELHI (Reuters) - India's federal drugs controller issued an alert on Thursday, asking states to ensure Swiss drugmaker Roche's cancer treatment Avastin was not administered to treat eyes, after its usage hampered vision in 15 patients.

Despite being a cancer drug, Avastin is often used by doctors globally for eye ailments even though it does not have U.S. Food and Drug Administration approval for that purpose.

Studies have shown eye injections of Avastin can curb vision loss.

However, fifteen patients at a hospital in western Gujarat state underwent surgery last week when they reported swelling and pain in their eyes following usage of Avastin.

The advisory, issued by India's top drugs regulator G.N. Singh, comes two days after Reuters reported Gujarat had asked distributors to recall one batch of the medicine, while the southern state of Telangana ordered a freeze on all its batches.

"Regulatory authorities may alert their inspectorate staff to monitor the movement of the said drug and its use in ophthalmology," Singh wrote in the alert notice, adding the drug was not approved in India for such usage.

Roche's India unit said it was aware of the government notification and reiterated it does not promote use of Avastin for eye ailments for which it does not have an approval.

Still, the company said on Tuesday it was taking events in Gujarat "very seriously" and initiated an internal probe.

The C.H. Nagri Municipal Eye Hospital in Gujarat's Ahmedabad city administered the drug to 7,000 people over the last decade but has now stopped.

Cases of shoddy medical treatment and spurious drugs are often reported in India, where the public health system remains overburdened and people, especially in smaller towns and villages, struggle to access basic health services.

Gujarat authorities are also investigating whether the drug involved in last week's incident was a fake copy of Avastin.

(Reporting by Aditya Kalra; Editing by Mark Potter)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 21 2016 | 9:49 PM IST

Next Story